Clinical trials: Diabetes Type II
Type 2 Diabetes Mellitus
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared with Acarbose when in Combination with…
- Trial name
- SMART (NCT02243176)
- Testing
- Saxagliptin, Acarbose
- Where
- China
- Volunteers
- 689 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type II
Multifactorial Treatment of Cardiovascular Risk in Diabetic Patients: Identification of Treatment Non-Responders
The aim of the study is to develop a model that allows early identification of type-2 diabetic patients who will face progressive atherosclerosis despite intensive, multifactorial, target oriented treatment
- Trial name
- CARDIONOR (NCT00660790)
- Testing
- Intensified Treatment of risk factors
- Where
- Austria
- Volunteers
- 97 people
- Sponsor
- Medical University of Graz
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
- Trial name
- GRADE (NCT01794143)
- Testing
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide)
- Where
- 36 sites in United States
- Volunteers
- 7,850 people
- Sponsor
- GRADE Study Group
Diabetes Mellitus, Type 2
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from…
- Trial name
- NCT00734474
- Testing
- LY2189265, Sitagliptin, Metformin
- Where
- 99 sites in United States, Canada and 11 more
- Volunteers
- 1,202 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
- Trial name
- NCT01285518
- Testing
- PF-05231023
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Cardiovascular Disease, Type 2 Diabetes
Complement and Cardiovascular Risk in Adolescents
This study evaluates how genetic variations in complement, a part of the immune system, affect cardiovascular risk in adolescents.
- Trial name
- CCRIA (NCT02821104)
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Type2 Diabetes Mellitus
Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)
The ultimate goal of this field trial is to systematically evaluate a novel care coordination tool for children with Type 2 Diabetes (T2D) in an office setting at Emory/Childrens Healthcare of Atlanta.
- Trial name
- GTG (NCT03926598)
- Testing
- Patient and/or Family Member Intervention, Certified Diabetes Educator Intervention, Physician Intervention
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Georgia Institute of Technology
Diabetes Mellitus, Type 2, Coronary Artery Disease
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
The purpose of this study is to determine whether bromodomain extraterminal domain (BET) inhibition treatment with RVX000222 in high-risk type 2 diabetes mellitus patients with coronary artery disease increases the time to major…
- Trial name
- BETonMACE (NCT02586155)
- Testing
- Apabetalone, Atorvastatin, Rosuvastatin
- Where
- 214 sites in Argentina, Australia and 13 more
- Volunteers
- 2,425 people
- Sponsor
- Resverlogix Corp
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy of the study drug tirzepatide in participants with type 2 diabetes mellitus.
- Trial name
- NCT03131687
- Testing
- tirzepatide, Dulaglutide
- Where
- 49 sites in United States, Poland and 2 more
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Non-Insulin-Dependent
A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)
A study to see if better control of type 2 diabetes can occur in patients taking a stable dose of metformin when they are also provided either sitagliptin or glimepiride.
- Trial name
- NCT00701090
- Testing
- sitagliptin, Comparator: glimepiride, open-label metformin
- Volunteers
- 1,035 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
- Trial name
- NCT00754624
- Testing
- Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
- Where
- 40 sites in United States, Bulgaria and 2 more
- Volunteers
- 229 people
- Sponsor
- Mannkind Corporation
Obesity, Type 2 Diabetes
PREMIER: PREvention of Metabolic Illness Through prEcision nutRition
Dietary intake is a major driving force behind the escalating obesity and type 2 diabetes epidemics. Large, high-quality clinical trials have shown that close adherence to healthy dietary recommendations significantly reduce the…
- Conditions
- Obesity, Type 2 Diabetes, Metabolic Syndrome, Diet Habit
- Trial name
- PREMIER (NCT04148482)
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Angina Pectoris, Coronary Artery Disease
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- TERISA (NCT01425359)
- Testing
- Ranolazine
- Where
- 135 sites in United States, Belarus and 12 more
- Volunteers
- 949 people
- Sponsor
- Gilead Sciences
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Effect of Diabetes Mellitus on Cholesterol Metabolism
HMG CoA reductase inhibitors (statins) are commonly used to treat high cholesterol (HC) in both type 1 and type 2 diabetes mellitus (DM).
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hypercholesterolemia
- Trial name
- NCT00879710
- Testing
- simvastatin or ezetimibe
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Medical College of Wisconsin
Type 2 Diabetes Mellitus With Hypoglycemia, Aging
Prepare for Your Diabetes Care
As adults with type 2 diabetes age, they are increasingly vulnerable to treatment-related hypoglycemia and its related complications (including hospitalization and death).
- Conditions
- Type 2 Diabetes Mellitus With Hypoglycemia, Aging, Patient Activation
- Trial name
- NCT05263310
- Testing
- Prepare for Your Diabetes Care, Usual Care
- Where
- United States
- Volunteers
- 672 people
- Sponsor
- Kaiser Permanente
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes
This trial was conducted in Asia, Europe and South America. The aim of this trial was to confirm efficacy of subject driven titration (individually adjusted) of biphasic insulin aspart 30 (BIAsp 30) twice daily in terms of…
- Trial name
- SimpleMix™ (NCT01427920)
- Testing
- biphasic insulin aspart 30
- Where
- 41 sites in Argentina, China and 4 more
- Volunteers
- 348 people
- Sponsor
- Novo Nordisk A/S
Diabetic Nephropathy
Effect of Sulodexide in Early Diabetic Nephropathy
The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.
- Trial name
- NCT00130208
- Testing
- Sulodexide
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 1,056 people
- Sponsor
- Keryx Biopharmaceuticals
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of sitagliptin and MK0431A in comparison to a commonly used medication in patients with type 2 diabetes.
- Trial name
- NCT00541450
- Testing
- Comparator: sitagliptin phosphate (sitagliptin), sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, Obesity
Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance.
- Trial name
- DOXY (NCT01375491)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego